TCGA-OR-A5J1-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.333
- PANCREAS_BETA_CELLS+0.230
- TGF_BETA_SIGNALING+0.145
- NOTCH_SIGNALING+0.100
- MYOGENESIS+0.083
- CHOLESTEROL_HOMEOSTASIS+0.069
- UV_RESPONSE_UP+0.049
- DNA_REPAIR+0.025
- APICAL_SURFACE+0.007
- APOPTOSIS-0.002
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.398
- INTERFERON_GAMMA_RESPONSE-0.305
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.302
- IL6_JAK_STAT3_SIGNALING-0.289
- E2F_TARGETS-0.288
- GLYCOLYSIS-0.255
- HYPOXIA-0.253
- G2M_CHECKPOINT-0.249
- ANGIOGENESIS-0.241
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.234
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A5DA-01A-11R-A27Q-07 | — | B | 0.796 |
| 2 | dab9a230-f4f6-4692-863a-5fdcf516be24 | — | — | 0.781 |
| 3 | BSR_10_0261_B3_S85 | — | A | 0.778 |
| 4 | MNG199 | — | — | 0.771 |
| 5 | ERR2598227 | fetal | fetal | 0.760 |
| 6 | SRR11296800 | — | — | 0.753 |
| 7 | BSR_06_0173_A4_S51 | — | A | 0.740 |
| 8 | SRR23303736 | — | — | 0.739 |
| 9 | SRR29022832 | — | A | 0.737 |
| 10 | ERR2208897 | — | — | 0.736 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.333 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.145 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.083 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.069 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.049 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.025 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.007 | Temsirolimus | — uncovered |